Private equity firm Warburg Pincus LLC has completed a partial exit in portfolio company, NASDAQ-listed China Biologic Products, receiving US$241.5 million in total proceeds, according to a regulatory filing. Warburg Pincus sold 2.3 million shares at US$105 per share, thereby lowering its stake to 34% from 44.2% before the sale. The buyout firm acquired its […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.